MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2026.1854219

Медицинская библиотека · Frontiers in pharmacology · 2026

Sacituzumab tirumotecan in an advanced HR+/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review.

Han Jing, Gao Juwei, Dou Fei, Ying Yinyin, Xu Zhaoyi, Mao Hairu, Zhang Weiping, Zhang Qinglin

Клинический случайСтатьяПеревод в очереди

Аннотация

BACKGROUND

Bone marrow metastasis (BMM) is an adverse prognostic factor in advanced breast cancer and may cause severe myelosuppression, particularly refractory thrombocytopenia, thereby limiting systemic therapy. Sacituzumab tirumotecan (sac-TMT) is a Trop-2-directed antibody-drug conjugate (ADC), but evidence for its use in patients with severe thrombocytopenia and compromised bone marrow reserve remains limited. We report a real-world case of sac-TMT use in this challenging clinical setting and discuss relevant considerations regarding ADC resistance and treatment sequencing.

CASE PRESENTATION: A 62-year-old postmenopausal woman (BMI: 16.23 kg/m2), with hypertension, hyperlipidemia, and no known family history of hereditary disease, was diagnosed in March 2015 with HR+/HER2 - breast cancer (pT1N2M0). She underwent right mastectomy with axillary dissection and immediate latissimus dorsi flap reconstruction, followed by four cycles of TC chemotherapy, adjuvant radiotherapy, and 6 years of tamoxifen. She relapsed in July 2021 with multiple bone metastases; after multiple lines of endocrine therapy and CDK4/6 inhibitors, her disease progressed. In September 2024 she was diagnosed with bone marrow metastases accompanied by severe refractory thrombocytopenia (nadir 12 × 10^9/L), unresponsive to conventional platelet-promoting therapies. In December 2024, sac-TMT was initiated together with platelet-supportive measures; during therapy platelets stabilized at ≥50 × 10^9/L, with no grade ≥3 non-hematologic adverse events, and disease stability exceeded 8 months.

CONCLUSION

Sac-TMT combined with intensive hematologic supportive care was feasible in this heavily pretreated HR+/HER2 - breast cancer patient with BMM-induced refractory thrombocytopenia. Platelet stabilization, reduced transfusion dependence, and clinical disease stability were observed before PET-CT-confirmed progression. Further case series and prospective studies are needed to validate the feasibility and safety of this approach in similar high-risk patients.

Для цитирования: Han Jing, Gao Juwei, Dou Fei, Ying Yinyin, Xu Zhaoyi, Mao Hairu, Zhang Weiping, Zhang Qinglin. Sacituzumab tirumotecan in an advanced HR+/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review.. Frontiers in pharmacology. 2026. DOI: 10.3389/fphar.2026.1854219.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.